Johnson & Johnson Debt to Equity Ratio 1986-2025 | JNJ
Current and historical debt to equity ratio values for Johnson & Johnson (JNJ) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Johnson & Johnson debt/equity for the three months ending September 30, 2025 was 0.44.
| Johnson & Johnson Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2025-09-30 |
$113.54B |
$79.28B |
1.43 |
| 2025-06-30 |
$114.92B |
$78.47B |
1.46 |
| 2025-03-31 |
$115.56B |
$78.11B |
1.48 |
| 2024-12-31 |
$108.61B |
$71.49B |
1.52 |
| 2024-09-30 |
$108.13B |
$70.16B |
1.54 |
| 2024-06-30 |
$109.55B |
$71.54B |
1.53 |
| 2024-03-31 |
$101.95B |
$70.02B |
1.46 |
| 2023-12-31 |
$98.78B |
$68.77B |
1.44 |
| 2023-09-30 |
$94.83B |
$71.23B |
1.33 |
| 2023-06-30 |
$115.28B |
$76.41B |
1.51 |
| 2023-03-31 |
$125.10B |
$70.87B |
1.77 |
| 2022-12-31 |
$110.57B |
$76.80B |
1.44 |
| 2022-09-30 |
$100.53B |
$74.60B |
1.35 |
| 2022-06-30 |
$101.37B |
$76.36B |
1.33 |
| 2022-03-31 |
$103.65B |
$74.71B |
1.39 |
| 2021-12-31 |
$108.00B |
$74.02B |
1.46 |
| 2021-09-30 |
$108.96B |
$70.27B |
1.55 |
| 2021-06-30 |
$106.86B |
$69.58B |
1.54 |
| 2021-03-31 |
$106.72B |
$65.83B |
1.62 |
| 2020-12-31 |
$111.62B |
$63.28B |
1.76 |
| 2020-09-30 |
$106.22B |
$64.47B |
1.65 |
| 2020-06-30 |
$95.40B |
$62.98B |
1.52 |
| 2020-03-31 |
$93.72B |
$61.29B |
1.53 |
| 2019-12-31 |
$98.26B |
$59.47B |
1.65 |
| 2019-09-30 |
$97.31B |
$58.21B |
1.67 |
| 2019-06-30 |
$94.33B |
$60.79B |
1.55 |
| 2019-03-31 |
$91.07B |
$58.96B |
1.55 |
| 2018-12-31 |
$93.20B |
$59.75B |
1.56 |
| 2018-09-30 |
$91.08B |
$64.63B |
1.41 |
| 2018-06-30 |
$92.48B |
$62.89B |
1.47 |
| 2018-03-31 |
$93.37B |
$63.26B |
1.48 |
| 2017-12-31 |
$97.14B |
$60.16B |
1.62 |
| 2017-09-30 |
$81.68B |
$73.98B |
1.10 |
| 2017-06-30 |
$80.89B |
$71.92B |
1.13 |
| 2017-03-31 |
$74.58B |
$70.34B |
1.06 |
| 2016-12-31 |
$70.79B |
$70.42B |
1.01 |
| 2016-09-30 |
$67.60B |
$72.77B |
0.93 |
| 2016-06-30 |
$67.34B |
$72.47B |
0.93 |
| 2016-03-31 |
$63.58B |
$72.65B |
0.88 |
| 2015-12-31 |
$62.26B |
$71.15B |
0.88 |
| 2015-09-30 |
$61.71B |
$71.55B |
0.86 |
| 2015-06-30 |
$60.91B |
$71.13B |
0.86 |
| 2015-03-31 |
$60.71B |
$67.88B |
0.89 |
| 2014-12-31 |
$60.61B |
$69.75B |
0.87 |
| 2014-09-30 |
$55.51B |
$76.59B |
0.73 |
| 2014-06-30 |
$57.15B |
$78.05B |
0.73 |
| 2014-03-31 |
$56.75B |
$76.58B |
0.74 |
| 2013-12-31 |
$58.63B |
$74.05B |
0.79 |
| 2013-09-30 |
$57.13B |
$69.80B |
0.82 |
| 2013-06-30 |
$54.66B |
$69.67B |
0.79 |
| 2013-03-31 |
$54.68B |
$66.86B |
0.82 |
| 2012-12-31 |
$56.52B |
$64.83B |
0.87 |
| 2012-09-30 |
$55.19B |
$63.76B |
0.87 |
| 2012-06-30 |
$55.32B |
$60.43B |
0.92 |
| 2012-03-31 |
$54.83B |
$61.37B |
0.89 |
| 2011-12-31 |
$56.56B |
$57.08B |
0.99 |
| 2011-09-30 |
$50.29B |
$61.53B |
0.82 |
| 2011-06-30 |
$49.98B |
$62.13B |
0.80 |
| 2011-03-31 |
$48.29B |
$59.86B |
0.81 |
| 2010-12-31 |
$46.33B |
$56.58B |
0.82 |
| 2010-09-30 |
$40.96B |
$57.29B |
0.72 |
| 2010-06-30 |
$39.45B |
$52.85B |
0.75 |
| 2010-03-31 |
$40.53B |
$52.91B |
0.77 |
| 2009-12-31 |
$44.09B |
$50.59B |
0.87 |
| 2009-09-30 |
$41.17B |
$50.38B |
0.82 |
| 2009-06-30 |
$41.19B |
$46.25B |
0.89 |
| 2009-03-31 |
$42.31B |
$43.79B |
0.97 |
| 2008-12-31 |
$42.40B |
$42.51B |
1.00 |
| 2008-09-30 |
$41.99B |
$45.73B |
0.92 |
| 2008-06-30 |
$41.68B |
$46.44B |
0.90 |
| 2008-03-31 |
$40.37B |
$45.63B |
0.89 |
| 2007-12-31 |
$37.64B |
$43.32B |
0.87 |
| 2007-09-30 |
$35.09B |
$43.57B |
0.81 |
| 2007-06-30 |
$31.56B |
$43.12B |
0.73 |
| 2007-03-31 |
$32.14B |
$40.93B |
0.79 |
| 2006-12-31 |
$31.24B |
$39.32B |
0.79 |
| 2006-09-30 |
$20.67B |
$40.57B |
0.51 |
| 2006-06-30 |
$20.25B |
$40.74B |
0.50 |
| 2006-03-31 |
$21.01B |
$41.12B |
0.51 |
| 2005-12-31 |
$20.15B |
$38.71B |
0.52 |
| 2005-09-30 |
$19.73B |
$36.85B |
0.54 |
| 2005-06-30 |
$19.38B |
$35.17B |
0.55 |
| 2005-03-31 |
$20.79B |
$33.65B |
0.62 |
| 2004-12-31 |
$21.50B |
$31.81B |
0.68 |
| 2004-09-30 |
$20.58B |
$31.51B |
0.65 |
| 2004-06-30 |
$20.12B |
$30.05B |
0.67 |
| 2004-03-31 |
$20.37B |
$28.49B |
0.72 |
| 2003-12-31 |
$21.39B |
$26.87B |
0.80 |
| 2003-09-30 |
$20.92B |
$25.74B |
0.81 |
| 2003-06-30 |
$21.22B |
$24.44B |
0.87 |
| 2003-03-31 |
$17.96B |
$24.04B |
0.75 |
| 2002-12-31 |
$17.86B |
$22.70B |
0.79 |
| 2002-09-30 |
$16.58B |
$22.09B |
0.75 |
| 2002-06-30 |
$16.46B |
$21.89B |
0.75 |
| 2002-03-31 |
$14.57B |
$23.72B |
0.61 |
| 2001-12-31 |
$14.26B |
$24.23B |
0.59 |
| 2001-09-30 |
$13.32B |
$23.73B |
0.56 |
| 2001-06-30 |
$13.39B |
$22.71B |
0.59 |
| 2001-03-31 |
$11.78B |
$20.09B |
0.59 |
| 2000-12-31 |
$13.85B |
$20.40B |
0.68 |
| 2000-09-30 |
$12.30B |
$18.49B |
0.67 |
| 2000-06-30 |
$12.33B |
$17.98B |
0.69 |
| 2000-03-31 |
$12.81B |
$17.15B |
0.75 |
| 1999-12-31 |
$12.95B |
$16.21B |
0.80 |
| 1999-09-30 |
$12.72B |
$15.38B |
0.83 |
| 1999-06-30 |
$12.38B |
$14.74B |
0.84 |
| 1999-03-31 |
$12.52B |
$14.22B |
0.88 |
| 1998-12-31 |
$12.62B |
$13.59B |
0.93 |
| 1998-09-30 |
$9.40B |
$13.94B |
0.67 |
| 1998-06-30 |
$9.00B |
$13.31B |
0.68 |
| 1998-03-31 |
$9.11B |
$12.81B |
0.71 |
| 1997-12-31 |
$9.09B |
$12.36B |
0.74 |
| 1997-09-30 |
$9.50B |
$12.18B |
0.78 |
| 1997-06-30 |
$9.28B |
$11.72B |
0.79 |
| 1997-03-31 |
$9.45B |
$11.17B |
0.85 |
| 1996-12-31 |
$9.17B |
$10.84B |
0.85 |
| 1996-09-30 |
$9.23B |
$10.68B |
0.87 |
| 1996-06-30 |
$9.07B |
$10.24B |
0.89 |
| 1996-03-31 |
$9.11B |
$9.83B |
0.93 |
| 1995-12-31 |
$8.83B |
$9.05B |
0.98 |
| 1995-09-30 |
$8.78B |
$8.91B |
0.99 |
| 1995-06-30 |
$8.83B |
$8.56B |
1.03 |
| 1995-03-31 |
$8.76B |
$7.88B |
1.11 |
| 1994-12-31 |
$8.55B |
$7.12B |
1.20 |
| 1994-09-30 |
$7.84B |
$6.99B |
1.12 |
| 1994-06-30 |
$6.82B |
$6.62B |
1.03 |
| 1994-03-31 |
$6.73B |
$6.09B |
1.11 |
| 1993-12-31 |
$6.67B |
$5.57B |
1.20 |
| 1993-09-30 |
$6.71B |
$5.70B |
1.18 |
| 1993-06-30 |
$6.51B |
$5.71B |
1.14 |
| 1993-03-31 |
$6.42B |
$5.54B |
1.16 |
| 1992-12-31 |
$6.71B |
$5.17B |
1.30 |
| 1992-09-30 |
$5.84B |
$5.97B |
0.98 |
| 1992-06-30 |
$5.53B |
$5.71B |
0.97 |
| 1992-03-31 |
$4.72B |
$5.74B |
0.82 |
| 1991-12-31 |
$4.89B |
$5.63B |
0.87 |
| 1991-09-30 |
$4.50B |
$5.36B |
0.84 |
| 1991-06-30 |
$4.37B |
$5.06B |
0.86 |
| 1991-03-31 |
$4.37B |
$4.93B |
0.89 |
| 1990-12-31 |
$4.61B |
$4.90B |
0.94 |
| 1990-09-30 |
$4.81B |
$4.74B |
1.01 |
| 1990-06-30 |
$4.62B |
$4.55B |
1.02 |
| 1990-03-31 |
$4.35B |
$4.29B |
1.02 |
| 1989-12-31 |
$3.77B |
$4.15B |
0.91 |
| 1989-09-30 |
$3.68B |
$3.93B |
0.94 |
| 1989-06-30 |
$3.85B |
$3.75B |
1.03 |
| 1989-03-31 |
$3.74B |
$3.62B |
1.03 |
| 1988-12-31 |
$3.62B |
$3.50B |
1.03 |
| 1988-09-30 |
$3.40B |
$3.51B |
0.97 |
| 1988-06-30 |
$3.49B |
$3.60B |
0.97 |
| 1988-03-31 |
$3.30B |
$3.67B |
0.90 |
| 1987-12-31 |
$3.06B |
$3.49B |
0.88 |
| 1987-09-30 |
$3.44B |
$3.29B |
1.05 |
| 1987-06-30 |
$3.34B |
$3.16B |
1.06 |
| 1987-03-31 |
$3.22B |
$3.02B |
1.07 |
| 1986-12-31 |
$3.05B |
$2.82B |
1.08 |
| 1985-12-31 |
$1.74B |
$3.35B |
0.52 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$450.090B |
$94.943B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
